Zofran
Recurrent Ovarian Carcinosarcoma
Mayo ClinicPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
4 Active assets in the Recurrent Ovarian Carcinosarcoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide Mayo Clinic | Phase 2 | BB |
Tolinapant National Cancer Institute (NCI) | Phase 1/2 | CC |
Bendamustine Mayo Clinic | Phase 1 | CC |
Autologous Muc1-Activated T-Cells Mayo Clinic | Phase 1 | CC |
Same molecule, other indications
Zofran is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →